Qingdao Haier Biomedical Co., Ltd.

Qingdao Haier Biomedical Co., Ltd. saw a notable rise in stock performance on May 22, 2026, reaching an intraday high. The company has outperformed the China Shanghai Composite in the short term, but faces long-term challenges, including a significant decline in net profit and historical underperformance against benchmarks.

Qingdao Haier Biomedical Co., Ltd. faced a notable decline in its stock, reflecting ongoing challenges. The company reported a significant drop in net profit and has experienced negative results for eight consecutive quarters. Its long-term performance shows substantial declines, indicating persistent financial difficulties in the industrial manufacturing sector.